The BLUE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLUE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BLUE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BLUE Detailed Price Forecast - CNN Money||View BLUE Detailed Summary - Google Finance|
|View BLUE Detailed Summary - Yahoo! Finance||View BLUE Stock Research & Analysis - Zacks.com|
|View BLUE Trends & Analysis - Trade-Ideas||View BLUE Major Holders - Barrons|
|View BLUE Call Transcripts - NASDAQ||View BLUE Breaking News & Analysis - Seeking Alpha|
|View BLUE Annual Report - CompanySpotlight.com||View BLUE OTC Short Report - OTCShortReport.com|
|View BLUE Fundamentals - TradeKing||View BLUE SEC Filings - Bar Chart|
|View Historical Prices for BLUE - The WSJ||View Performance/Total Return for BLUE - Morningstar|
|View the Analyst Estimates for BLUE - MarketWatch||View the Earnings History for BLUE - CNBC|
|View the BLUE Earnings - StockMarketWatch||View BLUE Buy or Sell Recommendations - MacroAxis|
|View the BLUE Bullish Patterns - American Bulls||View BLUE Short Pain Metrics - ShortPainBot.com|
|View BLUE Stock Mentions - StockTwits||View BLUE Stock Mentions - PennyStockTweets|
|View BLUE Stock Mentions - Twitter||View BLUE Investment Forum News - Investor Hub|
|View BLUE Stock Mentions - Yahoo! Message Board||View BLUE Stock Mentions - Seeking Alpha|
|View Insider Transactions for BLUE - SECform4.com||View Insider Transactions for BLUE - Insider Cow|
|View BLUE Major Holdings Summary - CNBC||View Insider Disclosure for BLUE - OTC Markets|
|View Insider Transactions for BLUE - Yahoo! Finance||View Institutional Holdings for BLUE - NASDAQ|
|View BLUE Stock Insight & Charts - FinViz.com||View BLUE Investment Charts - StockCharts.com|
|View BLUE Stock Overview & Charts - BarChart||View BLUE User Generated Charts - Trading View|
Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Posted on Saturday June 23, 2018
Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230. Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ: CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.
Today's Research Reports on Trending Tickers: bluebird bio and Exelixis
Posted on Thursday June 21, 2018
NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...
Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Posted on Tuesday June 19, 2018
LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on bluebird bio, Inc. (NASDAQ: BLUE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLUE as the Company's latest news hit the wire. On June 15, 2018, the Company announced that it will present new data from the completed Phase-1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase-3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, at the 23rd Annual Congress of the European Hematology Association in Stockholm on June 16, 2018. Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE: BPMX), which also belongs to the Healthcare sector as the Company bluebird bio.
Free Technical Research on BioPharmX and Three More Biotech Equities bio
Posted on Tuesday June 19, 2018
LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).